G1 Therapeutics Inc. [NASDAQ: GTHX] gained 13.60% or 2.78 points to close at $23.22 with a heavy trading volume of 1543365 shares. The company report on March 25, 2021 that G1 Therapeutics’ COSELA™ (trilaciclib) Included in Two Updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology.
COSELA Added to Both the NCCN Treatment Guidelines for Small Cell Lung Cancer and the NCCN Supportive Care Guidelines for Hematopoietic Growth Factors.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, announced that COSELA™ (trilaciclib) has been added to two updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®): the Treatment Guidelines for Small Cell Lung Cancer and the Supportive Care Guidelines for Hematopoietic Growth Factors. These guidelines document evidence-based, consensus-driven management to ensure that all patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes.
It opened the trading session at $19.77, the shares rose to $23.30 and dropped to $19.70, the range by which the price of stock traded the whole day. The daily chart for GTHX points out that the company has recorded 86.36% gains over the past six months. However, it is still -146.24% lower than its most recent low trading price.
If we look at the average trading volume of 1.57M shares, GTHX reached to a volume of 1543365 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about G1 Therapeutics Inc. [GTHX]:
Raymond James have made an estimate for G1 Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 17, 2020. While these analysts kept the previous recommendation, ROTH Capital raised their target price to Buy. The new note on the price target was released on June 26, 2020, representing the official price target for G1 Therapeutics Inc. stock. Previously, the target price had yet another raise from $72 to $82, while H.C. Wainwright kept a Buy rating on GTHX stock.
The Average True Range (ATR) for G1 Therapeutics Inc. is set at 2.05, with the Price to Sales ratio for GTHX stock in the period of the last 12 months amounting to 20.63. The Price to Book ratio for the last quarter was 4.98, with the Price to Cash per share for the same quarter was set at 5.15.
Trading performance analysis for GTHX stock
G1 Therapeutics Inc. [GTHX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.81. With this latest performance, GTHX shares dropped by -7.64% in over the last four-week period, additionally plugging by 86.36% over the last 6 months – not to mention a rise of 107.88% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GTHX stock in for the last two-week period is set at 51.04, with the RSI for the last a single of trading hit 53.40, and the three-weeks RSI is set at 50.76 for G1 Therapeutics Inc. [GTHX]. The present Moving Average for the last 50 days of trading for this stock 23.99, while it was recorded at 22.21 for the last single week of trading, and 18.36 for the last 200 days.
G1 Therapeutics Inc. [GTHX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and G1 Therapeutics Inc. [GTHX] shares currently have an operating margin of -213.04. G1 Therapeutics Inc.’s Net Margin is presently recorded at -219.18.
Return on Total Capital for GTHX is now -40.89, given the latest momentum, and Return on Invested Capital for the company is -42.22. Return on Equity for this stock declined to -45.86, with Return on Assets sitting at -38.67. When it comes to the capital structure of this company, G1 Therapeutics Inc. [GTHX] has a Total Debt to Total Equity ratio set at 16.21. Additionally, GTHX Total Debt to Total Capital is recorded at 13.95, with Total Debt to Total Assets ending up at 12.58. Long-Term Debt to Equity for the company is recorded at 15.65, with the Long-Term Debt to Total Capital now at 13.47.
Reflecting on the efficiency of the workforce at the company, G1 Therapeutics Inc. [GTHX] managed to generate an average of -$813,557 per employee. Receivables Turnover for the company is 382.15 with a Total Asset Turnover recorded at a value of 0.18.G1 Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.20 and a Current Ratio set at 9.20.
G1 Therapeutics Inc. [GTHX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, G1 Therapeutics Inc. posted -0.82/share EPS, while the average EPS was predicted by analysts to be reported at -0.98/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 16.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GTHX.
An analysis of insider ownership at G1 Therapeutics Inc. [GTHX]
There are presently around $595 million, or 72.80% of GTHX stock, in the hands of institutional investors. The top three institutional holders of GTHX stocks are: BLACKROCK INC. with ownership of 2,893,593, which is approximately 9.997% of the company’s market cap and around 1.30% of the total institutional ownership; MPM ONCOLOGY IMPACT MANAGEMENT LP, holding 2,847,588 shares of the stock with an approximate value of $66.12 million in GTHX stocks shares; and STATE STREET CORP, currently with $59.9 million in GTHX stock with ownership of nearly 9.071% of the company’s market capitalization.
Positions in G1 Therapeutics Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 64 institutional holders increased their position in G1 Therapeutics Inc. [NASDAQ:GTHX] by around 4,331,039 shares. Additionally, 55 investors decreased positions by around 8,390,732 shares, while 17 investors held positions by with 12,902,624 shares. The mentioned changes placed institutional holdings at 25,624,395 shares, according to the latest SEC report filing. GTHX stock had 16 new institutional investments in for a total of 263,372 shares, while 11 institutional investors sold positions of 1,220,328 shares during the same period.